A vs ABNB Stock Comparison

Scores Breakdown

Metric	A	ABNB
📈 Growth	18/30	14/30
💰 Profitability	16/20	18/20
🏦 Financial Health	7/20	15/20
💵 Valuation	9/20	10/20
⚠️ Risk (lower is better)	7/10	6/10
Overall Score	53/100	61/100

Side-by-Side Summaries

A Analysis	ABNB Analysis
📈 Growth & Financial Trajectory Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability. 💰 Margins & Cash Flow Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters. Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B. Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions. 🛡️ Balance Sheet & Liquidity Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows. ⚠️ Key Drivers & Risks Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation. Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.	📈 Growth & Financial Trajectory 8 quarters show revenue starting at 2.748B (2024 Q2) and ending at 2.678B (2026 Q1), a small decline; a peak of 4.095B in 2025 Q3 underscores episodic demand strength. Net income rose from 461M in 2024 Q2 to a high of 1.374B in 2025 Q3, then declined to 160M in 2026 Q1, highlighting volatility with a mid-period peak. 💰 Margins & Cash Flow Gross margin remains elevated, with gross_profit relative to revenue above ~75-85%; for 2026 Q1, gross_profit 2.097B vs. revenue 2.678B implies ~78% margin. Operating cash flow has been positive in most quarters, notably 1.708B in 2026 Q1 and 1.356B in 2025 Q3, while investing activities are generally negative and financing moves swing cash flow. 🛡️ Balance Sheet & Liquidity Balance sheet shows resilient assets of about $26.8B with current assets around $23.6B and equity near $7.64B in 2026 Q1; debt includes $2.48B long-term, supporting liquidity. This mix supports liquidity even in travel-cycle downturns, though elevated liabilities vs. equity suggest moderate leverage. ⚠️ Key Drivers & Risks Drivers: travel demand rebound, Airbnb network effects Risks: travel volatility, regulatory/competitive pressures, valuation sensitivity to growth deceleration

A Analysis

ABNB Analysis

📈 Growth & Financial Trajectory

Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability.

💰 Margins & Cash Flow

Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters.
Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B.
Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions.

🛡️ Balance Sheet & Liquidity

Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows.

⚠️ Key Drivers & Risks

Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation.
Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.

📈 Growth & Financial Trajectory

8 quarters show revenue starting at 2.748B (2024 Q2) and ending at 2.678B (2026 Q1), a small decline; a peak of 4.095B in 2025 Q3 underscores episodic demand strength. Net income rose from 461M in 2024 Q2 to a high of 1.374B in 2025 Q3, then declined to 160M in 2026 Q1, highlighting volatility with a mid-period peak.

💰 Margins & Cash Flow

Gross margin remains elevated, with gross_profit relative to revenue above ~75-85%; for 2026 Q1, gross_profit 2.097B vs. revenue 2.678B implies ~78% margin. Operating cash flow has been positive in most quarters, notably 1.708B in 2026 Q1 and 1.356B in 2025 Q3, while investing activities are generally negative and financing moves swing cash flow.

🛡️ Balance Sheet & Liquidity

Balance sheet shows resilient assets of about $26.8B with current assets around $23.6B and equity near $7.64B in 2026 Q1; debt includes $2.48B long-term, supporting liquidity. This mix supports liquidity even in travel-cycle downturns, though elevated liabilities vs. equity suggest moderate leverage.

⚠️ Key Drivers & Risks

Drivers: travel demand rebound, Airbnb network effects
Risks: travel volatility, regulatory/competitive pressures, valuation sensitivity to growth deceleration

Similar Companies

AMAT Score: 80 AME Score: 81 ANET Score: 84 GOOGL Score: 78 TMO Score: 75 WAT Score: 78

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"